From the Press

Dr Talia Cohen Solal, left, is using AI to help her and her team find the best antidepressants for patients

Genetika+ uses "Brain-in-a-Dish" technology to assess a patient's unique biomarkers via a blood sample and test against over 70 approved antidepressants and drug combinations, with plans to launch testing for American MDD patients in 2024.

Clexio and Genetika+ are partnering to screen and characterise Clexio's antidepressant pipeline using Genetika+'s iPSC-derived neurons platform, allowing for the first time an assessment of the functional effects of drugs directly on human neurons with biologically-relevant biomarkers that have been demonstrated to correlate with clinical response, and enabling the advancement of personalized medicine for psychiatry.

The EU-funded project WARN-D aims to predict who is at risk of depression and then develop a customised programme to prevent them from falling into it; the project's ultimate goal is to create an early warning system, which involves a smartphone application to monitor users’ mental health in real-time and detect when an individual is at risk of depression. By identifying people who are at risk of depression, the project hopes to help them stay mentally healthy for longer.

New personalised approaches to depression will either predict when a person is at risk to stop the condition in its tracks or target the illness with the optimum drug.

This week in our Startup Spotlight blog series is our 2021 XTC Healthcare Category Winner – Genetika+: Precision Medicine with “Brain-in-a-Dish”!

The pathway to effective treatment of MDD may be improved by multifaceted diagnostic tools, including but not limited to brain-in-a-dish technology.

NeuroKaire demonstrates high accuracy in predicting drug response in patients suffering from major depressive disorder

Through an Israeli startup's tech, physicians will soon be able to give patients a list of the antidepressants that would work best for them.

Kahn-Sagol-Maccabi (KSM) and Genetika+ form a research partnership to develop and validate AI that personalizes and speeds up an optimal depression treatment

ממחשוב קוונטי ועד צבעי מאכל, ומדיבוב סרטים עד גיוס עובדים. כמדי שנה, כתבי TheMarker בוחרים ב-20 חברות טכנולוגיה צעירות עם רעיונות גדולים

Find out more about the extraordinary work happening at Genetika+ as we bring precision medicine into practice to optimize depression treatment

Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market

Genetika+ personalizes treatment in the mental health space, initially focusing on depression. The Genetika+ platform uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Co-Sponsored by J.P. Morgan and Johnson & Johnson, Genetika+ Gives Award Winning Presentation

Biomed Israel hosts leaders in the field to speak how AI and machine learning tools and techniques change the way we discover and develop drugs.

Science Abroad hosts exposure workshop for biotech professionals all over Israel

How did a female-led startup from the MC18 Israel cohort turn their MassChallenge experience into a $10 million Series A funding round? Learn more about Genetika+ and its co-founders, Talia Cohen Solal and Daphna Laifenfeld, in our most recent case study.

Depression, historically, has been treated by trial and error until a therapy with a positive and stable outcome can be identified. Genetika+ is changing that with precision, personalized testing that enables the right antidepressant to be selected for patients the first time.

Proceeds to fund clinical trials and scale up in the U.S. market. New investment underscores the company’s promise to transform precision medicine and mental health.